Literature DB >> 7963689

Genetically modified skin to treat disease: potential and limitations.

G G Krueger1, J R Morgan, C M Jorgensen, L Schmidt, H L Li, M K Kwan, S T Boyce, H S Wiley, J Kaplan, M J Petersen.   

Abstract

Molecular definition of disease at the level of the gene and advances in recombinant DNA technology suggest that many diseases are amenable to correction by genes not bearing the defective elements that result in disease. Many questions must be answered before this therapy can be used to correct chronic diseases. These questions fall into safety and efficacy categories. Experience with transplanting cellular elements of skin or skin substitutes (defined as skin that possess the cell types and a dermal structure to develop into a functioning skin) to athymic rodents is considerable and is seen as a system where these questions can be answered. This paper reviews these questions and presents our early analysis of genetically modified cells in skin substitutes in vivo and in vitro. Experimental data demonstrate that both a matrix of woven nylon, housing a fibroblast generated collage, and dead dermis can be utilized to shuttle genetically modified human fibroblasts from the laboratory to an in vivo setting. Genetically modified fibroblasts do not migrate from the shuttle to the surrounding tissue. The survival of significant numbers, approximately 70%, of genetically modified fibroblasts for at least 6 weeks in these shuttles, supports this general approach as having clinical utility. It is also concluded that skin substitute systems can be used to generate a genetically modified skin in vitro that has the capacity to develop into functional skin in vivo. Further, as genetically modified keratinocytes differentiate there is increased production by the transgene, supporting the concept that keratinocytes have true potential as shuttles for therapeutic genes. This work demonstrates that transplantation of systems containing genetically modified cells of the skin can be used to experimentally define many aspects of gene therapy using skin before this technology is taken to the clinic. Examples include determining the effect of gene transduction and expression on structure and function of the genetically modified skin as well as on distant skin and an assessment of the translational capacity of the transgene as function of time and cell number.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7963689     DOI: 10.1111/1523-1747.ep12399100

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  7 in total

Review 1.  Tissue engineering of the vascular system: from capillaries to larger blood vessels.

Authors:  L Germain; M Rémy-Zolghadri; F Auger
Journal:  Med Biol Eng Comput       Date:  2000-03       Impact factor: 2.602

Review 2.  Gene therapy and wound healing.

Authors:  Sabine A Eming; Thomas Krieg; Jeffrey M Davidson
Journal:  Clin Dermatol       Date:  2007 Jan-Feb       Impact factor: 3.541

3.  Transcriptional control in keratinocytes and fibroblasts using synthetic ligands.

Authors:  R A Freiberg; S N Ho; P A Khavari
Journal:  J Clin Invest       Date:  1997-06-01       Impact factor: 14.808

4.  Safety and early efficacy outcomes for lentiviral fibroblast gene therapy in recessive dystrophic epidermolysis bullosa.

Authors:  Su M Lwin; Farhatullah Syed; Wei-Li Di; Tendai Kadiyirire; Lu Liu; Alyson Guy; Anastasia Petrova; Alya Abdul-Wahab; Fiona Reid; Rachel Phillips; Maria Elstad; Christos Georgiadis; Sophia Aristodemou; Patricia A Lovell; James R McMillan; John Mee; Snaigune Miskinyte; Matthias Titeux; Linda Ozoemena; Rashida Pramanik; Sonia Serrano; Racheal Rowles; Clarisse Maurin; Elizabeth Orrin; Magdalena Martinez-Queipo; Ellie Rashidghamat; Christos Tziotzios; Alexandros Onoufriadis; Mei Chen; Lucas Chan; Farzin Farzaneh; Marcela Del Rio; Jakub Tolar; Johann W Bauer; Fernando Larcher; Michael N Antoniou; Alain Hovnanian; Adrian J Thrasher; Jemima E Mellerio; Waseem Qasim; John A McGrath
Journal:  JCI Insight       Date:  2019-06-06

Review 5.  Skin substitutes from cultured cells and collagen-GAG polymers.

Authors:  S T Boyce
Journal:  Med Biol Eng Comput       Date:  1998-11       Impact factor: 2.602

Review 6.  Cultivation of human keratinocyte stem cells: current and future clinical applications.

Authors:  G Pellegrini; S Bondanza; L Guerra; M De Luca
Journal:  Med Biol Eng Comput       Date:  1998-11       Impact factor: 2.602

7.  Clonal analysis of stably transduced human epidermal stem cells in culture.

Authors:  M B Mathor; G Ferrari; E Dellambra; M Cilli; F Mavilio; R Cancedda; M De Luca
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-17       Impact factor: 11.205

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.